Diakonos Oncology Corp. closed its seed round to the tune of $11.4 million. Photo via Getty Images

A Houston-based, clinical-stage immuno-oncology company has raised an oversubscribed round of seed funding.

Diakonos Oncology Corp. closed its seed round to the tune of $11.4 million. The funding will go toward supporting the company's Phase 2 trial — slated for later this year, following its ongoing Phase 1 study — and operations through late next year. California-based biotechnology investment firm Restem Group Inc. led the round, and existing investors contributed as well.

“We greatly appreciate the support of these investors in sharing our passion for improving the lives of patients suffering from deadly cancers such as glioblastoma,” Mike Wicks, Diakonos CEO, says in a news release. “The fact that this financing is nearly triple our initial target also shows they share our confidence in the effectiveness of our unique cancer therapy.”

Founded in 2016, the company recently received FDA Fast Track designation for its dendritic cell vaccine, DOC1021, which targets glioblastoma multiforme, or GBM, the most common and most lethal malignant brain tumor in adults. Diakonos also received the designation for its pancreatic cancer treatment.

"We are thrilled to invest in this groundbreaking company that is at the forefront of cancer treatment innovation. As a firm deeply involved in the cell therapeutic field, we recognize the immense potential of their pioneering work with dendritic cell therapies and we are confident that this can become a new standard of care for cancer in the future," adds Andres Isaias, executive chairman of Restem Group Inc.

Diakonos Oncology's DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells. According to the company, all of the patients who have tried the treatment have exceeded survival expectations. And DOC1021 appears to be extremely safe, with no serious adverse effects having been reported.

A Houston health care company received the green light from the FDA to advance a treatment that's targeting a deadly cancer. Photo via Getty Images

Houston immunotherapy company achieves FDA designation for cancer-fighting vaccine

got the green light

The FDA has granted a Houston-based company a Fast Track designation.

Diakonos Oncology Corp. is a clinical-stage immuno-oncology company that has developed a unique dendritic cell vaccine, DOC1021. The vaccine targets glioblastoma multiforme (GBM), the most common and most lethal malignant brain tumor in adults. The aggressive tumors come with a life expectancy of about 15 months following diagnosis. About 7 percent of those diagnosed survive five years, while the 10-year outlook only sees a one-percent survival rate.

“The FDA’s decision acknowledges the potential of this new treatment approach for a very challenging disease,” Diakonos CEO Mike Wicks says in a press release. “Our protocol represents a first for cancer immunotherapy and could be viable for many types of cancers beyond GBM.”

FDA Fast Track designations are intended to expedite the haste with which drugs with early clinical promise are reviewed, likely taking them to market faster.

DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells.

The technology uses dendritic cells, white blood cells that are able to perceive threats, to its advantage. The unique cancer markers are loaded both internally and externally into the immune cells, just as they would simultaneously occur in a viral infection. The individualized treatment is administered through three precise injections that target deep cervical lymph node chains. By dosing this way, the immune responses are directed straight to the central nervous system.

The results have spoken for themselves: All of the patients who have tried the treatment have exceeded survival expectations. And just as importantly, DOC1021 appears to be extremely safe. No serious adverse effects have been reported.

“Because Phase I clinical trials are generally not statistically powered to demonstrate efficacy, detection of a statistically significant efficacy signal is very promising,” says William Decker, associate professor of immunology at Baylor College of Medicine and inventor of the DOC1021 technology.

The Phase 1 open-label trial of DOC1021 (NCT04552886) is currently taking place at both the University of Texas Health Science Center in Houston and at the MD Anderson Cancer Center at Cooper University Health Care in Camden, NJ. The trial is expected to complete this year.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston universities launch summer 2025 accelerators for student ventures

summer session

OwlSpark, a startup and small business accelerator for Rice University-affiliated ventures, has named the latest 11 companies to its program that focus on challenges across technology, health care, consumer products and other sectors. The program is hosted in tandem with the University of Houston’s RED Labs and will take place at the Ion.

The early-stage accelerator runs for 12 weeks and culminates at The Bayou Startup Showcase on July 31.

According to a news release from Rice, “the accelerator cultivates a vibrant environment where founders are empowered to build, test, and scale their ideas in a setting built for entrepreneurship.”

The program is divided into two tracks: one for high-growth tech startups and another for small businesses.

The latest OwlSpark class includes:

  • Web and mobile platform EasilyBEE, which boosts family and community engagement in K-12 schools
  • Diagnos, a wearable-integrated wellness platform that monitors health and prevents injuries in college athletes
  • Johnnie, an AI-powered records management software for rural and midsize first responder agencies
  • JustKindHumility, which offers faith-based travel journals
  • Klix, whichautomates early-stage clinical trial management from document screening to AI-driven patient outreach and eligibility checks
  • Lizzy’s Gourmet Gains, which offers high-protein, flavor-forward dips and dressings
  • NextStep, an AI-powered multilingual assistant helping underserved communities navigate resources for health care
  • A catheter-integrated sensor device PeriShield, which detects early infection in peritoneal dialysis patients
  • Right Design, which connects creatives with vetted employers, mentors and projects via job matching and commissions
  • UCoreAlly, which provides business support for biotech startups in marketing, business development, customer support, human resources and accounting
  • Ultrasound-based ablation system VentriTech that treats ventricular arrhythmias

The Owl Spark accelerator has supported 229 founders and launched 104 ventures with participants raising more than $116 million in funding since 2013, according to Rice.

UH also shared the 9 teams that will participate in RED Labs' latest cohort.

The latest RED Labs class includes:

  • BLEED, an art agency that helps artists commercialize their work by connecting art collectors to original artwork and artists
  • Brain Haven, which is developing nasal inhalers designed to stimulate the emotional and memory processing centers to preserve neuroplasticity and delay cognitive decline
  • Candi Wands Automated Cotton Candy, which has developed a continuously operating cotton candy machine to help entertainment venues boost passive revenue
  • ChériCollectible, a series of in-person events where Gen Z and collectors can buy, sell, and trade modern collectibles
  • JobRadar, a job board that uses AI to analyze and categorize positions in real-time and then apply candidates instantly
  • Stage Select LLC, a supplementary talent booking service that partners with multi-stage venues to help fill gaps in programming and increase profitability by finding and booking local talent for their "second stage."
  • P-LEGS, a pediatric lower-limb exoskeleton that reduces physical strain on therapists while delivering customizable gait training.
  • Roll ‘N’ Reel Photo Booth, an interactive event-based equipment rental business
  • Stayzy, which automates guest communication and handles maintenance issues with an AI-powered software for short-term rental companies that manage 20-plus rentals

Tesla's robotaxi service 'tentatively' to launch in Austin in June, Musk says

Tesla Talk

Elon Musk says Tesla is “tentatively” set to begin providing robotaxi service in Austin on June 22.

In a post on his X social media platform, Musk said the date could change because Tesla is “being super paranoid about safety.”

Investors, Wall Street analysts and Tesla enthusiasts have been anticipating the rollout of the driverless cabs since Musk said earlier this year that the service would launch in Austin sometime in June.

Last month, Musk told CNBC that the taxis will be remotely monitored at first and “geofenced” to certain areas of the city deemed the safest to navigate. He said he expected to initially run 10 or so taxis, increase that number rapidly and start offering the service in Los Angeles, San Antonio, San Francisco and other cities.

Musk has been promising fully autonomous, self-driving vehicles “next year” for a decade, but the pressure is on now as Tesla actually begins to operate a self-driving taxi service.

Sales of Tesla’s electric vehicles have sagged due to increased competition, the retooling of its most popular car, the Model Y, and the fallout from Musk’s turn to politics.

The Austin rollout also comes after Musk had a public blowup with President Donald Trump over the administration’s tax bill. Some analysts have expressed concern that Trump could retaliate by encouraging federal safety regulators to to step in at any sign of trouble for the robotaxis.